KEY FEATURES
Full Name | Large Multifunctional Peptidase 7 |
---|---|
Synonym | PSMB8; RING10; PSMB5i, Beta5i; Proteasome(Prosome,Macropain)Subunit,Beta Type 8; Multicatalytic endopeptidase complex subunit C13; Really interesting new gene 10 protein |
Assay Type | Sandwich |
Reactivity | Human |
Range | 0.31-20ng/mL |
Sensitivity | 0.12ng/mL |
Sample Type | Serum,plasma and other biological fluids |
Sample Volume | 100μL |
Detection Wavelength | OD450 |
Transportation Temperature | 2-8°C |
Specificity | The kit detected Human LMP7 in the samples and no significant cross-species reactions were found |
Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human LMP7. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human LMP7 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human LMP7, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human LMP7. You can calculate the concentration of Human LMP7 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
Components | Specifications | Storage and Notes |
---|---|---|
Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human LMP7 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
Intra-assay Precision | Inter-assay Precision | |||||
---|---|---|---|---|---|---|
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (ng/mL) | 1.07 | 1.75 | 7.74 | 1.13 | 1.59 | 7.98 |
Standard deviation | 0.07 | 0.08 | 0.37 | 0.07 | 0.09 | 0.34 |
CV(%) | 6.74 | 4.41 | 4.74 | 6.59 | 5.79 | 4.32 |
RECOVERY
The recovery of Human LMP7 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
Sample Type | Range (%) | Average Recovery (%) |
---|---|---|
Serum(n=8) | 86-100 | 93 |
EDTA plasma (n=8) | 94-107 | 99 |
Cell culture media (n=8) | 90-102 | 96 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human LMP7 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with LMP7 ELISA Kits
PSMB10 ELISA Kit | publications with LMP7 and PSMB10 |
ABCB3 ELISA Kit | publications with LMP7 and ABCB3 |
PSMB3 ELISA Kit | publications with LMP7 and PSMB3 |
PSMB6 ELISA Kit | publications with LMP7 and PSMB6 |
PSMB7 ELISA Kit | publications with LMP7 and PSMB7 |
PSMA6 ELISA Kit | publications with LMP7 and PSMA6 |
PSMB4 ELISA Kit | publications with LMP7 and PSMB4 |
Pathways associated with LMP7 ELISA Kit
APC/C-mediated Degradation Of Cell Cycle Proteins Pathway | APC/C-mediated Degradation Of Cell Cycle Proteins Pathway |
APC/C:Cdc20 Mediated Degradation Of Securin Pathway | APC/C:Cdc20 Mediated Degradation Of Securin Pathway |
APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway | APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway |
APC/C:Cdh1 Mediated Degradation Of Cdc20 And Other APC/C:Cdh1 Targeted Proteins In Late Mitosis/early G1 Pathway | APC/C:Cdh1 Mediated Degradation Of Cdc20 And Other APC/C:Cdh1 Targeted Proteins In Late Mitosis/early G1 Pathway |
Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway | Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway |
Activation Of NF-kappaB In B Cells Pathway | Activation Of NF-kappaB In B Cells Pathway |
Adaptive Immune System Pathway | Adaptive Immune System Pathway |
Antigen Processing-Cross Presentation Pathway | Antigen Processing-Cross Presentation Pathway |
Antigen Processing: Ubiquitination & Proteasome Degradation Pathway | Antigen Processing: Ubiquitination & Proteasome Degradation Pathway |
Apoptosis Pathway | Apoptosis Pathway |
Diseases associated with LMP7 ELISA Kit
Inflammation | publications with LMP7 and Inflammation |
Immune System Diseases | publications with LMP7 and Immune System Diseases |
Atrophy | publications with LMP7 and Atrophy |
Neoplasms | publications with LMP7 and Neoplasms |
Nervous System Diseases | publications with LMP7 and Nervous System Diseases |
Disease Models, Animal | publications with LMP7 and Disease Models, Animal |
Drug-Related Side Effects and Adverse Reactions | publications with LMP7 and Drug-Related Side Effects and Adverse Reactions |
Necrosis | publications with LMP7 and Necrosis |
Kidney Diseases | publications with LMP7 and Kidney Diseases |
Precancerous Conditions | publications with LMP7 and Precancerous Conditions |
Organs/Tissues associated with LMP7 ELISA Kit
Skin | publications with LMP7 and Skin |
Kidney | publications with LMP7 and Kidney |
Blood | publications with LMP7 and Blood |
Lung | publications with LMP7 and Lung |
Spleen | publications with LMP7 and Spleen |
Connective Tissue | publications with LMP7 and Connective Tissue |
Liver | publications with LMP7 and Liver |
Vascular | publications with LMP7 and Vascular |
Prostate | publications with LMP7 and Prostate |
Brain | publications with LMP7 and Brain |